27 October 2025 As IP plays a more important role in corporate valuations, acquirers are discovering that the biggest risks ...
Merck Serono has failed to convince a US appeals court to overturn a PTAB decision invalidating two dosing regimen patents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback